Frontlight ResearchEarly access
CompletedNo phase
Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor
Key facts
- Who runs it
- University of Copenhagen
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 25 people enrolled
- Started
- 13 Aug 2019
- Ended
- 28 Nov 2023
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- GIP-A
- Placebo
- Record updated
- 29 November 2023
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients under clinical investigation of acromegaly disease with normal kidney function, liver function and hemoglobin levels
Who cannot take part
- Medication for acromegaly, adenectomy, liver disease, uncontrolled anemia, severe heart disease, uncontrolled high blood pressure (>170/100 mmHg), current pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Modulation of the GIP System in Patients With Acromegaly Due to a Pituitary adenoma
The 2 groups in the trial
- GIP-AOther group
Infusion of GIP-A alone as a study tool.
- PlaceboPlacebo, for comparison
Saline
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Modulating the Glucose-dependent Insulinotropic Polypeptide (GIP) System in Patients With Acromegaly Due to a Pituitary Tumor
- Record updated
- 29 November 2023